Literature DB >> 34927715

MERS-CoV in the COVID-19 era: update from Saudi Arabia, 2019-2020.

Anas Khan1, Sharafaldeen Bin Nafisah2, Bandr Mzahim2, Bakhitah Aleid3, Daliah Almatrafi2, Abdullah Assiri4, Hani Jokhdar4.   

Abstract

BACKGROUND: The prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) infection during the period of coronavirus disease 2019 (COVID-19) remains uncertain. AIMS: This study aimed to provide an update on the epidemiology of MERS-CoV in Saudi Arabia from January 2019 to October 2020.
METHODS: Data on all laboratory-confirmed cases of MERS-CoV infection in Saudi Arabia from January 2019 to 20 October 2020 were retrieved from the Health Electronic Surveillance Network of the Ministry of Health of Saudi Arabia. Data collected were: demographic characteristics of cases, clinical course of the infection, related mortality and association with exposure to confirmed cases or camels.
RESULTS: In total, 299 cases of MERS-CoV infection were reported in the study period. The mean age of cases was 52.4 years. Most of the cases were males (78.9%) and had comorbidities (72.7%), and 11.9% of cases were health care providers. Of the 299 cases, 83 (27.7%) died. Older age and having comorbidities were associated with higher mortality. Exposure to camels was associated with lower mortality. Health care providers also had a lower mortality rate than non-health care providers. Compared with COVID-19, MERS-CoV infection still has a higher mortality rate but with a more predictable pattern and an anticipated deterioration.
CONCLUSION: MERS-CoV infection remains a public health concern. The percentage of cases that were health care providers (11.9%) is lower than previously reported (19.1-25.0%), possibly due to the various preventive measures put in place to control COVID-19.
Copyright © World Health Organization (WHO) 2021. Open Access. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO license (https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Entities:  

Keywords:  COVID-19; Middle East respiratory syndrome coronavirus; Saudi Arabia; health personnel; public health

Mesh:

Year:  2021        PMID: 34927715     DOI: 10.26719/emhj.21.049

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  3 in total

1.  [Preliminary application study of dual-robotic navigated minimally invasive treatment by TiRobot and Artis Zeego on pelvic fractures].

Authors:  Kexin Liu; Mengzhen You; Moran Huang; Cheng Chen; Biyu Rui; Hong Gao; Yunfeng Chen; Xiaolin Li; Wei Zhang; Yuqiang Sun; Lei Wang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-08-15

Review 2.  Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.

Authors:  Qiaoshuai Lan; Lijue Wang; Fanke Jiao; Lu Lu; Shuai Xia; Shibo Jiang
Journal:  J Med Virol       Date:  2022-09-13       Impact factor: 20.693

3.  A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.

Authors:  Qiaoshuai Lan; Jasper Fuk-Woo Chan; Wei Xu; Lijue Wang; Fanke Jiao; Guangxu Zhang; Jing Pu; Jie Zhou; Shuai Xia; Lu Lu; Kwok-Yung Yuen; Shibo Jiang; Qian Wang
Journal:  Viruses       Date:  2022-03-06       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.